Publications

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG 2nd. J Neurooncol. 2009 May;93(1):61-77. Epub 2009 May 9. Review.

Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.  Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR.Radiology. 2009 Mar;250(3):665-73.

Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH. Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20.

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. Epub 2008 Jun 17.